ReviewImmune network2026
Regulatory T Cell Heterogeneity in the Steady State and Tumor.
Review in Immune network, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Review
- Tumor-adapted regulatory T cells: Molecular reprogramming, immune suppression, and therapeutic targeting in cancer.Molecular biology reports · 2026Review
- Costimulation loss enhances IL-2-driven Treg generation by PI3K-STAT3 inhibition in CNS autoimmunity.EMBO molecular medicine · 2026Article
- Dynamic Interplay Between Tumor Cells and the Immune System.Immune network · 2026Article
- Bidirectional regulatory mechanisms and therapeutic prospects of tumor hypercoagulable state and immunosuppressive tumor microenvironment.Oncology reviews · 2026Review
- Regulatory T cells in pregnancy disorders: a multi-dimensional framework for biomarkers and therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tregs are essential for maintaining immune homeostasis and preventing autoimmunity. In the steady state, Tregs adopt distinct developmental, cytokine-dependent, and tissue-adapted programs that induce substantial heterogeneity across tissues. This diversity supports their context-dependent roles in maintaining barrier integrity, regulating inflammation, and supporting tissue repair. In the tumor microenvironment, Tregs are further differentiated in response to chronic antigen stimulation and local environmental cues, generating tumor-infiltrating Tregs with specialized suppressive functions. This review integrates insights from developmental pathways, tissue residency programs, transcriptional profiling, and tumor-specific adaptation, highlighting the current understanding of Treg heterogeneity in the steady state and tumor. Finally, we discuss therapeutic strategies designed to selectively target tumor-resident Tregs while preserving systemic immune tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.